Latest Zealand Pharma News & Updates

See the latest news and media coverage for Zealand Pharma. We track all announcements, press releases, and industry mentions in real time, all in one place.

Zealand Pharma

Biotechnology company developing peptide and small-molecule medicines

zealandpharma.com

Headquarters: Søborg (Copenhagen), Denmark
Founded year: 1998
Company type: Public company
Number of employees: 640–1,000
Industry: Biotechnology & Medical Research

Last updated October 17

Latest news about Zealand Pharma

In short: Zealand Pharma advanced petrelintide into Phase 3, posted positive Phase 2 and survodutide data, and signed new partnerships.

Company announcements

October 13 Zealand Pharma

Zealand Pharma partners with Generate Biomedicines for AI protein therapeutics

The collaboration involves up to USD 1.2 billion in milestones and utilizes generative AI to develop multispecific proteins for metabolic diseases.

October 7 Zealand Pharma

Zealand Pharma announces positive Phase 2 petrelintide results

Petrelintide achieved up to 9.2% weight loss with favorable safety profiles for patients with obesity and type 2 diabetes.

October 1 Zealand Pharma

Zealand Pharma reports survodutide results achieving significant weight loss

Boehringer Ingelheim’s drug met primary endpoints in the SYNCHRONIZE-2 Phase III trial, showing up to 13.1% weight loss and improved glycemic control in patients with obesity and type 2 diabetes.

September 29 Zealand Pharma

Zealand Pharma publishes petrelintide Phase 2 data showing weight loss

Results published in The Lancet show double-digit weight loss and improved cardiometabolic factors, alongside a favorable tolerability profile.

Media coverage

October 17 BioPharm International

WuXi Biologics Subsidiary in $3-Billion Vaccine Manufacturing Contract | BioPharm International

Once-weekly amylin analog petrelintide produced up to 9.2% weight loss at 28 weeks in adults with obesity and type 2 diabetes, Zealand Pharma reports.

October 16 Avisen Danmark

Zealand Pharma enters into billion-dollar deal with Swiss

Zealand Pharma, headquartered in Søborg, will receive Swiss assistance to launch its weight-loss drug Petrilintid. (Archive photo). Photo: Thomas Traasdahl/Ritzau Scanpix The Danish...

October 13 Finans

Zealand may enter into billion-dollar deal with Generate - pays $30 million upfront

On Tuesday, Zealand Pharma entered into a strategic collaboration agreement with Generate Biomedicines for the development of multispecific protein treatments for obesity and other metabolic diseases.

October 7 RTTNews

Zealand Reports Improved Weight Reduction With Petrelintide In Phase 2 ZUPREME-2...

Zealand Pharma A/S (ZEAL.CO), a biotechnology company, reported on Wednesday promising topline results from the Phase 2 ZUPREME-2 trial evaluating petrelintide in treating obese or...

Never miss news about Zealand Pharma

Track Zealand Pharma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Zealand Pharma competitors & trending companies

Browse news for competitors to Zealand Pharma and other trending companies.